These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 39187068)

  • 1. Prevalence, clinical significance and prognosis value of liver stiffness measurement anomalies in transthyretin cardiac amyloidosis.
    Lointier E; Cariou E; Beneyto M; Fournier P; Lavie-Badie Y; Eyharts D; Bureau C; Lairez O;
    Int J Cardiol; 2024 Dec; 416():132485. PubMed ID: 39187068
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Wild-type transthyretin cardiac amyloidosis is not rare in elderly subjects: the CATCH screening study.
    Aimo A; Vergaro G; Castiglione V; Fabiani I; Barison A; Gentile F; Ferrari Chen YF; Giorgetti A; Genovesi D; Buda G; Franzini M; Piepoli M; Moscardini S; Rapezzi C; Fontana M; Passino C; Emdin M
    Eur J Prev Cardiol; 2024 Aug; 31(11):1410-1417. PubMed ID: 38456769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence, characteristics and outcomes of older patients with hereditary versus wild-type transthyretin amyloid cardiomyopathy.
    Porcari A; Razvi Y; Masi A; Patel R; Ioannou A; Rauf MU; Hutt DF; Rowczenio D; Gilbertson J; Martinez-Naharro A; Venneri L; Whelan C; Lachmann H; Wechalekar A; Quarta CC; Merlo M; Sinagra G; Hawkins PN; Fontana M; Gillmore JD
    Eur J Heart Fail; 2023 Apr; 25(4):515-524. PubMed ID: 36644836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes of clinical characteristics, distribution of red flags and prognosis in contemporary patients with wild-type transthyretin amyloidosis cardiomyopathy.
    Sanne Bøjet L; Bertil L; Anders Lehmann Dahl P; Jens Kæstel S; Tor Skibsted C; Steen Hvitfeldt P
    Ann Med; 2024 Dec; 56(1):2398735. PubMed ID: 39247984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence, Characteristics, and Impact on Prognosis of Aortic Stenosis in Patients With Cardiac Amyloidosis.
    Annabi MS; Carter-Storch R; Zaroui A; Galat A; Oghina S; Kharoubi M; Bezard M; Derumeaux G; Fanen P; Lemonnier F; Poullot E; Itti E; Gallet R; Teiger E; Pibarot P; Damy T; Clavel MA
    J Am Heart Assoc; 2024 Jul; 13(13):e034723. PubMed ID: 38904242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new staging system for cardiac transthyretin amyloidosis.
    Gillmore JD; Damy T; Fontana M; Hutchinson M; Lachmann HJ; Martinez-Naharro A; Quarta CC; Rezk T; Whelan CJ; Gonzalez-Lopez E; Lane T; Gilbertson JA; Rowczenio D; Petrie A; Hawkins PN
    Eur Heart J; 2018 Aug; 39(30):2799-2806. PubMed ID: 29048471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Right Ventricular Strain Improves the Echocardiographic Diagnosis and Risk Stratification of Transthyretin Cardiac Amyloidosis Among Other Phenotypes of Left Ventricular Hypertrophy.
    Ozbay B; Satyavolu BS; Rearick C; Soman P; Katz WE; Sezer A; Sade LE
    J Am Soc Echocardiogr; 2024 Oct; 37(10):947-959. PubMed ID: 38942217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Native T1 and Extracellular Volume in Transthyretin Amyloidosis.
    Martinez-Naharro A; Kotecha T; Norrington K; Boldrini M; Rezk T; Quarta C; Treibel TA; Whelan CJ; Knight DS; Kellman P; Ruberg FL; Gillmore JD; Moon JC; Hawkins PN; Fontana M
    JACC Cardiovasc Imaging; 2019 May; 12(5):810-819. PubMed ID: 29550324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carpal tunnel syndrome and spinal canal stenosis: harbingers of transthyretin amyloid cardiomyopathy?
    Aus dem Siepen F; Hein S; Prestel S; Baumgärtner C; Schönland S; Hegenbart U; Röcken C; Katus HA; Kristen AV
    Clin Res Cardiol; 2019 Dec; 108(12):1324-1330. PubMed ID: 30953182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of survival stratification in patients with wild-type cardiac amyloidosis.
    Siepen FAD; Bauer R; Voss A; Hein S; Aurich M; Riffel J; Mereles D; Röcken C; Buss SJ; Katus HA; Kristen AV
    Clin Res Cardiol; 2018 Feb; 107(2):158-169. PubMed ID: 28956153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biomarkers and Prediction of Prognosis in Transthyretin-Related Cardiac Amyloidosis: Direct Comparison of Two Staging Systems.
    Cappelli F; Martone R; Gabriele M; Taborchi G; Morini S; Vignini E; Allinovi M; Di Gioia M; Bartolini S; Di Mario C; Perfetto F
    Can J Cardiol; 2020 Mar; 36(3):424-431. PubMed ID: 32145869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequency of hereditary transthyretin amyloidosis among elderly patients with transthyretin cardiomyopathy.
    Maestro-Benedicto A; Vela P; de Frutos F; Mora N; Pomares A; Gonzalez-Vioque E; Briceño A; Cabrera E; Cobo-Marcos M; Dominguez F; Gonzalez-Lopez E; Segovia J; Lara-Pezzi E; Garcia-Pavia P
    Eur J Heart Fail; 2022 Dec; 24(12):2367-2373. PubMed ID: 35999650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes in Cardiac Transthyretin Amyloidosis and Association With New York Heart Association Class: Real-World Data.
    Müller ML; Latinova E; Brand A; Mattig I; Spethmann S; Messroghli D; Hahn K; Landmesser U; Heidecker B
    J Am Heart Assoc; 2024 Jul; 13(14):e033478. PubMed ID: 38958150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amyloid myopathy: expanding the clinical spectrum of transthyretin amyloidosis-case report and literature review.
    Ungericht M; Wanschitz J; Kroiss AS; Röcken C; Schuetz T; Messner M; Zaruba MM; Loescher WN; Poelzl G
    J Nucl Cardiol; 2023 Aug; 30(4):1420-1426. PubMed ID: 35581484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence, Incidence, and Impact on Mortality of Conduction System Disease in Transthyretin Cardiac Amyloidosis.
    Donnellan E; Wazni OM; Saliba WI; Hanna M; Kanj M; Patel DR; Wilner B; Kochar A; Jaber WA
    Am J Cardiol; 2020 Aug; 128():140-146. PubMed ID: 32650908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiac Amyloidosis: Overlooked, Underappreciated, and Treatable.
    Rubin J; Maurer MS
    Annu Rev Med; 2020 Jan; 71():203-219. PubMed ID: 31986086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transthyretin amyloidosis prevalence and characteristics in Korean patients with heart failure with preserved or mildly reduced ejection fractions.
    Kim SE; Lee SH; Oh J; Lee CJ; Hwang SH; Kang WJ; Kang SM
    Sci Rep; 2024 Oct; 14(1):22863. PubMed ID: 39354040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sex Differences in Transthyretin Cardiac Amyloidosis: Unraveling the Complexities in Epidemiology, Pathophysiology, Diagnosis, and Treatment.
    Vilches S; Martínez-Avial M; Méndez I; Gómez González C; Espinosa MÁ
    Curr Heart Fail Rep; 2024 Aug; 21(4):344-353. PubMed ID: 38775878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiac amyloidosis is not a single disease: a multiparametric comparison between the light chain and transthyretin forms.
    Neculae G; Adam R; Jercan A; Bădeliță S; Tjahjadi C; Draghici M; Stan C; Bax JJ; Popescu BA; Marsan NA; Coriu D; Jurcuț R
    ESC Heart Fail; 2024 Oct; 11(5):2825-2834. PubMed ID: 38757395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic utility of the Perugini grading of 99mTc-DPD scintigraphy in transthyretin (ATTR) amyloidosis and its relationship with skeletal muscle and soft tissue amyloid.
    Hutt DF; Fontana M; Burniston M; Quigley AM; Petrie A; Ross JC; Page J; Martinez-Naharro A; Wechalekar AD; Lachmann HJ; Quarta CC; Rezk T; Mahmood S; Sachchithanantham S; Youngstein T; Whelan CJ; Lane T; Gilbertson JA; Rowczenio D; Hawkins PN; Gillmore JD
    Eur Heart J Cardiovasc Imaging; 2017 Dec; 18(12):1344-1350. PubMed ID: 28159995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.